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Perspectives on Assurance Case Development for
Retinal Disease Diagnosis using Deep Learning
Chiara Picardi and Ibrahim Habli
University of York, York YO10 5DD, UK
{chiara.picardi,ibrahim.habli}@york.ac.uk
Abstract. We report our experience with developing an assurance case
for a deep learning system used for retinal disease diagnosis and referral.
We investigate how an assurance case could clarify the scope and struc-
ture of the primary argument and identify sources of uncertainty. We also
explore the need for an assurance argument pattern that could provide
developers with a reusable template for communicating and structuring
the different claims and evidence and clarifying the clinical context rather
than merely focusing on meeting or exceeding performance measures.
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1 Introduction
Justifying the use of machine learning in critical healthcare applications is cur-
rently a significant technological and societal challenge [5]. The developers and
clinical users of the technology have to assure, prior to deployment, different crit-
ical properties such as safety, performance, usability and cost-effectiveness [6].
This challenge can be refined further into 2 parts. Firstly, there is no consensus
on the assurance criteria or specific properties that machine learning systems
have to exhibit for them to be accepted by the public or by the clinical and
regulatory authorities, i.e. what is good enough? Secondly, there is very little
guidance, e.g. standards, on accepted means for achieving such properties [6].
In this paper, we investigate the extent to which an explicit assurance case
could inform a decision concerning the use of machine learning in clinical diag-
nosis. An assurance case is “a reasoned and compelling argument, supported by a
body of evidence, that a system, service or organisation will operate as intended
for a defined application in a defined environment” [1]. An assurance case is
considered as a generalisation of a safety case, i.e. where safety claims are the
focus of the assurance.
We build on the results of De Fauw et al [2] on the use of a deep learning sys-
tem for diagnosis and referral in retinal disease. This system comprises 2 different
neural networks. The first network, called Segmentation Network, takes as input
three-dimensional Optical Coherence Tomography (OCT) scans and creates a
detailed device-independent tissue-segmentation map. The second network ex-
amines the segmentation map and outputs one of the four referral suggestions in
addition to the presence or absence of multiple concomitant retinal pathologies.
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Through an assurance case, our objectives are to (1) clarify structure of the
primary argument and the clinical context and (2) identify sources of uncertainty.
The contribution of the paper is that it provides a self-contained assurance case
for a deep learning system, thereby highlighting assurance issues that have to be
considered explicitly beyond merely exceeding a specific performance measure.
2 Assurance Case
The assurance case is represented using the Goal Structuring Notation (GSN)
[1]. GSN is a generic argument structuring language that is widely used in the
safety-critical domain. The reader is advised to consult the publicly available
GSN standard [1] for a more detailed description of the notation. Due to the
space limitation, we focus the discussion on 2 assurance argument fragments:
1. Segmentation network assurance argument (Figure 1, Section 2.1)
2. Classification network assurance argument (Figure 2, Section 2.2)
These arguments capture the essence of the justification based on perfor-
mance against clinical experts. The clinical context in the assurance case is
the ophthalmology referral pathway at Moorfields Eye Hospital, from which the
training, validation and test data is provided. At this stage, the scope of the
claims is limited to this clinical setting with no evidence for generalisation (de-
spite the wide and diverse population served). It is important to note that the
assurance case focuses exclusively on the chain of reasoning and evidence based
on the data in the original study [2]. The extent to which this assurance case
could be improved, or its scope extended, is discussed in Section 3.
2.1 Segmentation Network Assurance Argument
Figure 1 shows the assurance argument fragment concerning the performance
and transparency of the segmentation network. The argument makes a distinc-
tion between the scans that include ambiguous and unambiguous regions. The
context is important here, referencing the data used for training, testing and
validation. It also clarifies the profile of the clinical experts involved in the seg-
mentation experiment. Evidence of sufficient performance is provided based on
two different scanning devices (99.21% and 99.93%). The argument clarifies fur-
ther that for unambiguous regions, the network produces tissue-segmentation
maps that are comparable to manual segmentation. For scans with ambiguous
regions, the network provides different (but plausible) interpretations of the low
quality regions, i.e. similar to how the different human experts might produce
different interpretations. The evidence is represented by supplementary videos
that show the multiple hypotheses of the segmentation maps produced by the
network. An important aspect of creating a separate network for segmentation
is greater transparency. By being able to inspect the tissue-segmentation map
(and not just referral decisions), clinicians have clearer means for understand-
ing the basis for the final clinical decision. What is less clear, however, is the
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Fig. 1. Segmentation Network Assurance Argument
effectiveness of this visualisation, i.e. degree of acceptance by clinical experts.
As such, this is labelled as ‘to be developed’ (small diamond below the claim).
2.2 Classification Network Assurance Argument
The argument in Figure 2 states the primary claim that the system achieves
or in some cases exceeds human expert performance in retinal disease diagnosis
and referral. Experts comprise 4 retina specialists with respective 21, 21, 13 and
12 years of experience and 4 optometrists with respective 15, 9, 6 and 3 years
of experience. Two sessions were organised. In the first session experts were
required to give the referral suggestions using the OCT scans only. In the second
session they were also able to use fundus images and clinical notes. Similar to the
segmentation network assurance argument, this argument communicates clearly
the training, test and validation data as well as the benchmark against which
performance is assessed (i.e. gold standard and expert profiles).
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Classificat ion Network Claim
Classification network achieves 
or exceeds expert performance 
with t issue segmentation maps 
as input
Experts Profiles
4 retina specialists with 
21, 21, 13 and 12 years 
of experience and 4 
optometrists with 15, 9, 6 
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14884 scans for 7621 
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Evidence
Results on 
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Test  Data
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grader 
Classificat ion Network
3-dimensional version of 
dense blocks using 3?× ?3?
× ?1 and 1?× ?1?× ?3 
convolutions
Fig. 2. Classification Network Assurance Argument
3 Discussion
We reflect on the insights gained and lessons learned from different perspectives.
Performance-based Arguments. Evidence in machine learning studies
tends to focus on meeting or exceeding certain performance criteria. The assur-
ance argument above is consistent with this approach. Importantly, it ensures
that the different training, test and validation datasets are explicitly referenced
in addition to the performance results. It clarifies, particularly to non-technical
reviewers and decision makers, the importance of appraising the quality of these
datasets and the extent to which the data used is relevant to the context in which
the performance claims are made. The argument also prompts the reviewers to
question the performance criteria used.
Assurance Case Pattern. By looking at the argument fragments for the
Segmentation and Classification Networks, a pattern of reasoning seems to emerge
(Figure 3). Such a pattern could prompt the developers and assessors of machine
learning to more explicitly consider the relevance and appropriateness of the con-
textual and evidential data, i.e. ensuring sufficient confidence in the quality and
relevance of the data and models, by scrutinising the links in the argument in
Figure 3, rather than merely exceeding a specific performance measure.
Assumptions and Transparency. An assurance case can help ensure that
the assumptions made are explicitly listed. For example, the reviewers of the case
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Fig. 3. Preliminary Machine Learning Assurance Argument Pattern
can question the profiles and representativeness of the clinical experts involved in
the experiments and the extent to which further clarification might be necessary.
Transparency in how the machine makes clinical decisions is also important.
Here, the assurance case clarifies that transparency is limited to the output of
the segmentation and not the classification network, i.e. prompting the reviewer
to question the need for transparency in the final diagnosis and referral decision.
Safety and Regulations. Although our assurance case does not directly ad-
dress patient safety [3], there remain fundamental questions as what is deemed
as good enough for assuring the safety of machine learning. For example, are
arguments based on exceeding human equivalence or appealing to risk-benefit
evidence acceptable? How do we address non-quantifiable factors such as those
related to human or organisational factors? Another issue is the readiness of the
regulators to review, challenge and approve machine learning evidence. Kelly in
[4] talks about the Imbalance of Skills between the developers and the indepen-
dent assessors of novel technologies as a major hurdle for effective assurance case
practices. The readiness of regulators to appraise machine learning algorithms,
evaluation evidence and deployment constraints is an ongoing concern.
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